1-13 of 13
Shuchita Kaila
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Frontline Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma - Real-World Evidence from a Large Community-Based Oncology Practice Network in the US

Lucio Gordan, Amanda Warner, Hannah Granger, Amy Ming, Cindy Chen, Nicole Rafalko, Jennifer S. Harper, Niodita Gupta-Werner, Rohan Medhekar, Shuchita Kaila, Annelore Cortoos, Trevor Heritage
Journal: Blood
Blood (2024) 144 (Supplement 1): 2395.
https://doi.org/10.1182/blood-2024-204730
Published: 2024
Journal Articles

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA

Sikander Ailawadhi, Sarah M. Larson, Shannon Ferrante, Nicole Rafalko, Niodita Gupta-Werner, Jennifer S. Harper, Rohan Medhekar, Marjohn Armoon, Annelore Cortoos, Shuchita Kaila, Shebli Atrash
Journal: Blood
Blood (2024) 144 (Supplement 1): 2381.
https://doi.org/10.1182/blood-2024-199085
Published: 2024
Journal Articles

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Carlyn Rose Tan, Lucio Gordan, Rachel Dileo, Prerna Mewawalla, Sarah M. Larson, Faith E Davies, David Oveisi, Niodita Gupta-Werner, Rohan Medhekar, Annelore Cortoos, Marjohn Armoon, Alvi Rahman, Claire Vanden Eynde, Marie-Hélène Lafeuille, John Reitan, Gary Milkovitch, Joseph Bubalo, Adam Forman, Douglas W Sborov, Shuchita Kaila, Saad Z. Usmani
Journal: Blood
Blood (2024) 144 (Supplement 1): 3760.
https://doi.org/10.1182/blood-2024-201712
Published: 2024
Journal Articles

Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma

Doris K. Hansen, Santosh Gautam, Marie-Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Anabelle Tardif-Samson, Philippe Thompson-Leduc, Alex Z. Fu, Annelore Cortoos, Shuchita Kaila, Rafael Fonseca
Journal: Blood
Blood (2023) 142 (Supplement 1): 543.
https://doi.org/10.1182/blood-2023-187233
Published: 2023
Journal Articles

Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Lucio Gordan, Rohan Medhekar, Alex Z. Fu, Abril Oliva Ramirez, Nicolle Bonar, Bao-Ngoc Nguyen, Michaela Spence, Rebecca McTavish, Tim Disher, Shuchita Kaila, Anjan J. Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1963.
https://doi.org/10.1182/blood-2023-180829
Published: 2023
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Multiple Myeloma Patients at Mayo Clinic

Scott Soefje, Corinne Carpenter, Katherine Carlson, Samir Awasthi, Thomas S. Lin, Shuchita Kaila, Daniel Tarjan, Nikhil Kayal, Christian Kirkup, Tyler Wagner, Kathleen Gray, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 2717.
https://doi.org/10.1182/blood-2021-149012
Published: 2021
Journal Articles

Characteristics and Treatment of Patients with Multiple Myeloma Who Received Daratumumab in a Large Claims Database in the United States

Snow X Feng, Alex Z. Fu, Vipin Khare, Augustina Ogbonnaya, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 4031.
https://doi.org/10.1182/blood-2021-149001
Published: 2021
Journal Articles

Real-World Patient Characteristics and Treatment Outcomes Among Newly Diagnosed Multiple Myeloma Patients Initiating Daratumumab, Lenalidomide, and Dexamethasone As First-Line Therapy

Ming-Hui Tai, Qian Cai, Alex Z. Fu, Vipin Khare, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 1979.
https://doi.org/10.1182/blood-2021-149002
Published: 2021
Journal Articles

Patient Characteristics, Treatment Patterns and Outcomes Among Black and White Patients with Multiple Myeloma Initiating Daratumumab: A Real-World Chart Review Study

Shebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie-Hélène Lafeuille, Patrick Lefebvre, Adriana C Rossi
Journal: Blood
Blood (2021) 138 (Supplement 1): 1965.
https://doi.org/10.1182/blood-2021-145941
Published: 2021
Journal Articles

Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy

Rohan Medhekar, Tao Ran, Alex Z. Fu, Sharmila Patel, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 3782.
https://doi.org/10.1182/blood-2021-153416
Published: 2021
Journal Articles

Use of Anti-Infective Prophylaxis in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Initiating Treatment with Daratumumab

Ming-Hui Tai, PhD, Eric M. Ammann, PhD, Shuchita Kaila, PhD, Christopher Pericone, Ajaybir Singh, Thomas S. Lin, MD PhD, Faith E. Davies
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134086
Published: 2020
Journal Articles

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Eric M. Ammann, PhD, Annette Lam, MSc, Wenze Tang, MPH, Tobias Kampfenkel, MD, Mohit Sharma, Charlene Lee, MSc, Shuchita Kaila, PhD, Alex Z. Fu, PhD, Kathleen Gray, PhD, Jianming He, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-139882
Published: 2020